Intellia Therapeutics
Nasdaq NTLA · Cambridge, MA
Works in Cardiovascular · Dermatology · Genetic & rare · GI & liver · Hematology · Immunology · Metabolic & endocrine · Neurology · Respiratory
Intellia Therapeutics is a clinical trial sponsor based in Cambridge, MA, listed as Nasdaq NTLA. It has 6 active clinical trials with 1,549 planned participants, across 9 therapeutic areas. Since 2021 it has completed 1 trial and stopped 2 early.
Trial track record · since 2021
Financials · Nasdaq NTLA
Pipeline · 6 active trials
| Stage | Trial | Status |
|---|---|---|
Questions about Intellia Therapeutics
Intellia Therapeutics is lead sponsor of 6 active clinical trials on ClinicalTrials.gov, with 1,549 planned participants, in Cardiovascular, Dermatology, Genetic & rare, GI & liver and other areas. Since 2021 it has completed 1 trial and stopped 2 early.
Intellia Therapeutics is based in Cambridge, MA and is listed as Nasdaq NTLA. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Intellia Therapeutics; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-08.
Approve Suite is not affiliated with Intellia Therapeutics.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.